Is it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems?

Basit Öğe Kaydı
dc.authorid0000-0003-2003-6337
dc.authorid0000-0002-8084-7855
dc.contributor.authorTopuk, Savaş
dc.contributor.authorAkyuva, Yener
dc.contributor.authorKaraaslan, Numan
dc.contributor.authorMutlu, Çağri Ata
dc.contributor.authorYılmaz, İbrahim
dc.contributor.authorİşyar, Mehmet
dc.contributor.authorŞirin, Duygu Yaşar
dc.contributor.authorAkkaya, Semih
dc.contributor.authorÖzbek, Hanefi
dc.contributor.authorMahiroğulları, Mahir
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:43Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:43Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalı
dc.descriptionWOS: 000407701900010
dc.descriptionPubMed ID: 28641566
dc.description.abstractPurpose: The present study aimed to analyze the researches that are at the experimental phase concerning osteosarcoma treatment. The researches included drug delivery systems which allow controlled release and imbue small interfering-/micro-ribonucleic acid. Methods: Without any language preference, we searched US National Library of Medicine National Institutes of Health, Embase, OVID, Cochrane Library database of clinical trials from 1843 to May 25, 2016 and traced all the references of incorporated documents. The data were evaluated using descriptive statistics and the results are shown as frequency (%). Results: We haven't encountered any drug delivery system in which Small interfering ribonucleic acid/ micro ribonucleic acid oligonucleotides were embedded successfully against osteosarcoma. There has been only one research in which hairpin-ribonucleic acid was embedded. Conclusion: It was considered that drug delivery system enabling controlled oligonucleotide release in the treatment period of osteosarcoma was not projected for the clinical use. However, it cannot be neglected that the mentioned experimental studies with regard to osteosarcoma treatment establish the basis of target therapies. The method in question looks promising regarding effective treatment of osteosarcoma in the future.
dc.identifier.citationTopuk, S., Akyuva, Y., Karaaslan, N., Mutlu, Ç. A., Yılmaz, İ., İşyar, M. ... Mahiroğulları, M. (2017). Is it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems? Current Pharmaceutical Biotechnology, 18(6), 516-522. https://dx.doi.org/10.2174/1389201018666170615083455
dc.identifier.doi10.2174/1389201018666170615083455
dc.identifier.endpage522
dc.identifier.issn1389-2010
dc.identifier.issn1873-4316
dc.identifier.issue6
dc.identifier.scopusqualityQ2
dc.identifier.startpage516
dc.identifier.urihttps://dx.doi.org/10.2174/1389201018666170615083455
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2272
dc.identifier.volume18
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publishers Ltd
dc.relation.ispartofCurrent Pharmaceutical Biotechnologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectControlled Release
dc.subjectDrug Delivery Systems
dc.subjectmiRNA
dc.subjectOsteosarcoma
dc.subjectsiRNA
dc.subjectPharmacogenomics
dc.titleIs it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu